[Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
Identifieur interne : 000159 ( Main/Exploration ); précédent : 000158; suivant : 000160[Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
Auteurs : J. Barth ; T. Hammerschmidt [Allemagne] ; J. Vollmar [Allemagne] ; M. Bierbaum ; O. SchöffskiSource :
- Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) [ 1439-4421 ] ; 2014.
Descripteurs français
- KwdFr :
- Allemagne (MeSH), Commerce (MeSH), Coûts et analyse des coûts (législation et jurisprudence), Coûts et analyse des coûts (économie), Europe (MeSH), Frais et honoraires (législation et jurisprudence), Législation sur les produits chimiques ou pharmaceutiques (économie), Maîtrise des coûts (MeSH), Politique de santé (législation et jurisprudence), Politique de santé (économie), Union européenne (MeSH), Vaccins antigrippaux (ressources et distribution), Vaccins antigrippaux (économie), Valeurs de référence (MeSH).
- MESH :
- législation et jurisprudence : Coûts et analyse des coûts, Frais et honoraires, Politique de santé.
- ressources et distribution : Vaccins antigrippaux.
- économie : Coûts et analyse des coûts, Législation sur les produits chimiques ou pharmaceutiques, Politique de santé, Vaccins antigrippaux.
- Allemagne, Commerce, Europe, Maîtrise des coûts, Union européenne, Valeurs de référence.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Commerce (MeSH), Cost Control (MeSH), Costs and Cost Analysis (economics), Costs and Cost Analysis (legislation & jurisprudence), Europe (MeSH), European Union (MeSH), Fees and Charges (legislation & jurisprudence), Germany (MeSH), Health Policy (economics), Health Policy (legislation & jurisprudence), Influenza Vaccines (economics), Influenza Vaccines (supply & distribution), Legislation, Drug (economics), Reference Values (MeSH).
- MESH :
- chemical , economics : Influenza Vaccines.
- chemical , supply & distribution : Influenza Vaccines.
- geographic : Europe, Germany.
- economics : Costs and Cost Analysis, Health Policy, Legislation, Drug.
- legislation & jurisprudence : Costs and Cost Analysis, Fees and Charges, Health Policy.
- Commerce, Cost Control, European Union, Reference Values.
Abstract
OBJECTIVES
On 01 January 2011 the bill for the reorganisation of the pharmaceutical market became effective. Since that time there is a European reference pricing (ERP) system for vaccines in order to bring down the German vaccine prices to an assumed lower European level. This study describes the implementation, functioning and effect of this new system. For influenza vaccines the impact of ERP on the price level and spread of prices is analysed.
METHODS
The description of the mechanism is based on the law and corresponding regulations of the head association of sickness funds (GKV-SV). The analysis of vaccine prices is based on the data of the i:data report (status of 01 September 2011) of ifap Service Institute.
RESULTS
The European reference price is calculated as the average price of the manufacturer-selling-prices of the corresponding vaccine in the 4 countries of the European Union whose gross national income comes closest to the German one and in which the vaccine is distributed. The relied prices are weighted by sales and purchasing power parities of the respective countries. This analysis suggests that in particular the practical implementation of the reference price system should be further improved and specified. The calculation of the reference prices should ensure price comparability. In addition, significant problems remain in the deduction of discounts, because no distinction is made in the documentation of vaccinating doctors, whether vaccination was performed as a compulsory or statutory benefit. The comparison of the manufacturer-selling-prices of individual influenza vaccines with the corresponding reference prices shows an enlargement of the existing price differences, which have evolved in a competitive environment, after the implementation of the reference pricing -system.
CONCLUSIONS
There is still a need for improvement in implementing the reference pricing system. In the most competitive vaccine market of influenza vaccines, the ERP-system lowers the prices, but seems to distort the market prices.
DOI: 10.1055/s-0033-1351272
PubMed: 24081570
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].</title><author><name sortKey="Barth, J" sort="Barth, J" uniqKey="Barth J" first="J" last="Barth">J. Barth</name><affiliation><nlm:affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</nlm:affiliation><wicri:noCountry code="subField">Universität Erlangen-Nürnberg</wicri:noCountry></affiliation></author><author><name sortKey="Hammerschmidt, T" sort="Hammerschmidt, T" uniqKey="Hammerschmidt T" first="T" last="Hammerschmidt">T. Hammerschmidt</name><affiliation wicri:level="3"><nlm:affiliation>GlaxoSmithKline GmbH & Co. KG, München.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><wicri:orgArea>GlaxoSmithKline GmbH & Co. KG</wicri:orgArea></affiliation></author><author><name sortKey="Vollmar, J" sort="Vollmar, J" uniqKey="Vollmar J" first="J" last="Vollmar">J. Vollmar</name><affiliation wicri:level="3"><nlm:affiliation>GlaxoSmithKline GmbH & Co. KG, München.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><wicri:orgArea>GlaxoSmithKline GmbH & Co. KG</wicri:orgArea></affiliation></author><author><name sortKey="Bierbaum, M" sort="Bierbaum, M" uniqKey="Bierbaum M" first="M" last="Bierbaum">M. Bierbaum</name><affiliation><nlm:affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</nlm:affiliation><wicri:noCountry code="subField">Universität Erlangen-Nürnberg</wicri:noCountry></affiliation></author><author><name sortKey="Schoffski, O" sort="Schoffski, O" uniqKey="Schoffski O" first="O" last="Schöffski">O. Schöffski</name><affiliation><nlm:affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</nlm:affiliation><wicri:noCountry code="subField">Universität Erlangen-Nürnberg</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24081570</idno><idno type="pmid">24081570</idno><idno type="doi">10.1055/s-0033-1351272</idno><idno type="wicri:Area/Main/Corpus">000188</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000188</idno><idno type="wicri:Area/Main/Curation">000188</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000188</idno><idno type="wicri:Area/Main/Exploration">000188</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].</title><author><name sortKey="Barth, J" sort="Barth, J" uniqKey="Barth J" first="J" last="Barth">J. Barth</name><affiliation><nlm:affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</nlm:affiliation><wicri:noCountry code="subField">Universität Erlangen-Nürnberg</wicri:noCountry></affiliation></author><author><name sortKey="Hammerschmidt, T" sort="Hammerschmidt, T" uniqKey="Hammerschmidt T" first="T" last="Hammerschmidt">T. Hammerschmidt</name><affiliation wicri:level="3"><nlm:affiliation>GlaxoSmithKline GmbH & Co. KG, München.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><wicri:orgArea>GlaxoSmithKline GmbH & Co. KG</wicri:orgArea></affiliation></author><author><name sortKey="Vollmar, J" sort="Vollmar, J" uniqKey="Vollmar J" first="J" last="Vollmar">J. Vollmar</name><affiliation wicri:level="3"><nlm:affiliation>GlaxoSmithKline GmbH & Co. KG, München.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><wicri:orgArea>GlaxoSmithKline GmbH & Co. KG</wicri:orgArea></affiliation></author><author><name sortKey="Bierbaum, M" sort="Bierbaum, M" uniqKey="Bierbaum M" first="M" last="Bierbaum">M. Bierbaum</name><affiliation><nlm:affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</nlm:affiliation><wicri:noCountry code="subField">Universität Erlangen-Nürnberg</wicri:noCountry></affiliation></author><author><name sortKey="Schoffski, O" sort="Schoffski, O" uniqKey="Schoffski O" first="O" last="Schöffski">O. Schöffski</name><affiliation><nlm:affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</nlm:affiliation><wicri:noCountry code="subField">Universität Erlangen-Nürnberg</wicri:noCountry></affiliation></author></analytic><series><title level="j">Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</title><idno type="eISSN">1439-4421</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Commerce (MeSH)</term><term>Cost Control (MeSH)</term><term>Costs and Cost Analysis (economics)</term><term>Costs and Cost Analysis (legislation & jurisprudence)</term><term>Europe (MeSH)</term><term>European Union (MeSH)</term><term>Fees and Charges (legislation & jurisprudence)</term><term>Germany (MeSH)</term><term>Health Policy (economics)</term><term>Health Policy (legislation & jurisprudence)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (supply & distribution)</term><term>Legislation, Drug (economics)</term><term>Reference Values (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (MeSH)</term><term>Commerce (MeSH)</term><term>Coûts et analyse des coûts (législation et jurisprudence)</term><term>Coûts et analyse des coûts (économie)</term><term>Europe (MeSH)</term><term>Frais et honoraires (législation et jurisprudence)</term><term>Législation sur les produits chimiques ou pharmaceutiques (économie)</term><term>Maîtrise des coûts (MeSH)</term><term>Politique de santé (législation et jurisprudence)</term><term>Politique de santé (économie)</term><term>Union européenne (MeSH)</term><term>Vaccins antigrippaux (ressources et distribution)</term><term>Vaccins antigrippaux (économie)</term><term>Valeurs de référence (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term><term>Germany</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Costs and Cost Analysis</term><term>Health Policy</term><term>Legislation, Drug</term></keywords><keywords scheme="MESH" qualifier="legislation & jurisprudence" xml:lang="en"><term>Costs and Cost Analysis</term><term>Fees and Charges</term><term>Health Policy</term></keywords><keywords scheme="MESH" qualifier="législation et jurisprudence" xml:lang="fr"><term>Coûts et analyse des coûts</term><term>Frais et honoraires</term><term>Politique de santé</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Coûts et analyse des coûts</term><term>Législation sur les produits chimiques ou pharmaceutiques</term><term>Politique de santé</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Commerce</term><term>Cost Control</term><term>European Union</term><term>Reference Values</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term><term>Commerce</term><term>Europe</term><term>Maîtrise des coûts</term><term>Union européenne</term><term>Valeurs de référence</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>On 01 January 2011 the bill for the reorganisation of the pharmaceutical market became effective. Since that time there is a European reference pricing (ERP) system for vaccines in order to bring down the German vaccine prices to an assumed lower European level. This study describes the implementation, functioning and effect of this new system. For influenza vaccines the impact of ERP on the price level and spread of prices is analysed.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The description of the mechanism is based on the law and corresponding regulations of the head association of sickness funds (GKV-SV). The analysis of vaccine prices is based on the data of the i:data report (status of 01 September 2011) of ifap Service Institute.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The European reference price is calculated as the average price of the manufacturer-selling-prices of the corresponding vaccine in the 4 countries of the European Union whose gross national income comes closest to the German one and in which the vaccine is distributed. The relied prices are weighted by sales and purchasing power parities of the respective countries. This analysis suggests that in particular the practical implementation of the reference price system should be further improved and specified. The calculation of the reference prices should ensure price comparability. In addition, significant problems remain in the deduction of discounts, because no distinction is made in the documentation of vaccinating doctors, whether vaccination was performed as a compulsory or statutory benefit. The comparison of the manufacturer-selling-prices of individual influenza vaccines with the corresponding reference prices shows an enlargement of the existing price differences, which have evolved in a competitive environment, after the implementation of the reference pricing -system.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>There is still a need for improvement in implementing the reference pricing system. In the most competitive vaccine market of influenza vaccines, the ERP-system lowers the prices, but seems to distort the market prices.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24081570</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4421</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</Title><ISOAbbreviation>Gesundheitswesen</ISOAbbreviation></Journal><ArticleTitle>[Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].</ArticleTitle><Pagination><MedlinePgn>e7-e13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0033-1351272</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">On 01 January 2011 the bill for the reorganisation of the pharmaceutical market became effective. Since that time there is a European reference pricing (ERP) system for vaccines in order to bring down the German vaccine prices to an assumed lower European level. This study describes the implementation, functioning and effect of this new system. For influenza vaccines the impact of ERP on the price level and spread of prices is analysed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The description of the mechanism is based on the law and corresponding regulations of the head association of sickness funds (GKV-SV). The analysis of vaccine prices is based on the data of the i:data report (status of 01 September 2011) of ifap Service Institute.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The European reference price is calculated as the average price of the manufacturer-selling-prices of the corresponding vaccine in the 4 countries of the European Union whose gross national income comes closest to the German one and in which the vaccine is distributed. The relied prices are weighted by sales and purchasing power parities of the respective countries. This analysis suggests that in particular the practical implementation of the reference price system should be further improved and specified. The calculation of the reference prices should ensure price comparability. In addition, significant problems remain in the deduction of discounts, because no distinction is made in the documentation of vaccinating doctors, whether vaccination was performed as a compulsory or statutory benefit. The comparison of the manufacturer-selling-prices of individual influenza vaccines with the corresponding reference prices shows an enlargement of the existing price differences, which have evolved in a competitive environment, after the implementation of the reference pricing -system.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is still a need for improvement in implementing the reference pricing system. In the most competitive vaccine market of influenza vaccines, the ERP-system lowers the prices, but seems to distort the market prices.</AbstractText><CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barth</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammerschmidt</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline GmbH & Co. KG, München.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vollmar</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline GmbH & Co. KG, München.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bierbaum</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schöffski</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Funktionsweise und Auswirkungen des Referenzpreissystems bei Impfstoffen nach §130a Abs. 2 SGB V: eine Analyse am Beispiel der Grippeimpfstoffe.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Gesundheitswesen</MedlineTA><NlmUniqueID>9204210</NlmUniqueID><ISSNLinking>0941-3790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003132" MajorTopicYN="N">Commerce</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003363" MajorTopicYN="N">Cost Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation & jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005062" MajorTopicYN="N">European Union</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005249" MajorTopicYN="N">Fees and Charges</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation & jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation & jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000600" MajorTopicYN="Y">supply & distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007880" MajorTopicYN="N">Legislation, Drug</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24081570</ArticleId><ArticleId IdType="doi">10.1055/s-0033-1351272</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li></region><settlement><li>Munich</li></settlement></list><tree><noCountry><name sortKey="Barth, J" sort="Barth, J" uniqKey="Barth J" first="J" last="Barth">J. Barth</name><name sortKey="Bierbaum, M" sort="Bierbaum, M" uniqKey="Bierbaum M" first="M" last="Bierbaum">M. Bierbaum</name><name sortKey="Schoffski, O" sort="Schoffski, O" uniqKey="Schoffski O" first="O" last="Schöffski">O. Schöffski</name></noCountry><country name="Allemagne"><region name="Bavière"><name sortKey="Hammerschmidt, T" sort="Hammerschmidt, T" uniqKey="Hammerschmidt T" first="T" last="Hammerschmidt">T. Hammerschmidt</name></region><name sortKey="Vollmar, J" sort="Vollmar, J" uniqKey="Vollmar J" first="J" last="Vollmar">J. Vollmar</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000159 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000159 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24081570
|texte= [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24081570" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |